

Stock Code: 600380

Stock Short Name: 健康元

Joincare Pharmaceutical Group Industry Co., Ltd.

2024 Third Quarterly Report

The Board of Directors and all Directors of the Company hereby warrant that there are no false representations, misleading statements or material omissions contained in this announcement and accept legal responsibility for the truthfulness, accuracy and completeness of the contents hereof.

IMPORTANT NOTICE:

- The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this quarterly report, and that there are no false representations, misleading statements or material omissions contained herein, and severally and jointly accept legal responsibility.
- The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
- Whether the third quarterly financial statements have been audited.

Yes No

I. MAJOR FINANCIAL DATA

(I) Major Accounting Data and Financial Indicators

Unit: Yuan Currency: RMB

Item	For the Reporting Period	YoY change (%)	From the beginning of the year to the end of the Reporting Period	YoY change (%)
Revenues	3,664,194,805.57	-6.80	11,898,828,905.02	-5.95
Net profit attributable to Shareholders of the listed company	335,135,597.05	24.95	1,111,560,063.92	2.58

Net profit attributable to Shareholders of the listed company after deduction of extraordinary gain and loss	311,474,846.35	16.45	1,073,381,416.07	2.30
Net cash flow from operating activities	N/A	N/A	2,613,605,501.06	6.25
Basic earnings per share (RMB/share)	0.18	26.01	0.59	4.63
Diluted earnings per share (RMB/share)	0.18	26.79	0.59	4.97
Weighted average return on net assets (%)	2.32	Increased by 0.39 percentage points	7.82	Decreased by 0.40 percentage points
	As at the end of the Reporting Period	As at the end of the previous year		Change in the ending amount of the Reporting Period to that of the previous year (%)
Total assets	36,172,500,281.87	36,358,126,258.82		-0.51
Net assets attributable to Shareholders of the listed company	14,487,774,610.56	13,755,901,924.06		5.32

Notes: 1. The “Reporting Period” represents the 3-month period from the beginning to the end of this quarter, the same below.

2. From January to September 2024, the Company’s Chemical pharmaceuticals achieved revenues of RMB5,879 million, representing a year-on-year decrease of 10.55%. Among them, revenues from gonadotropic hormones products reached RMB2,308 million, representing a year-on-year increase of 5.46%; revenues from gastroenterology products reached RMB1,854 million, representing a year-on-year decrease of 18.66%; revenues from respiratory formulation products reached RMB799 million, representing a year-on-year decrease of 28.18%; revenues from psychiatry products reached RMB443 million, representing a year-on-year increase of 3.11%; and revenues from anti-infective products reached RMB322 million, representing a year-on-year decrease of 19.46%. Revenues from APIs and intermediates amounted to RMB3,857 million, representing a year-on-year decrease of 2.83%. Revenues from traditional Chinese medicine (TCM) formulations were RMB1,084 million, representing a year-on-year decrease of 16.06%. Revenues from diagnostic reagents and equipment were RMB566 million, representing a year-on-year increase of 21.03%. Revenues from health care products amounted to RMB262 million, representing a year-on-year increase of 97.67%, while revenues from biological products reached RMB131 million, representing a year-on-year increase of 15.98%.

3. From January to September 2024, the Company realized net profit attributable to shareholders of the parent of RMB1,112 million, of which Joincare (excluding Livzon Group and Livzon MAB) realized net profit attributable to shareholders of the parent of approximately RMB479 million, representing a YoY decrease of approximately 21.65%, and the impact of Livzon MAB on the net profit attributable to shareholders of the parent was approximately negative RMB164 million.

(II) Items and Amounts of Extraordinary Gains and Losses

√Applicable □N/A

Unit: Yuan Currency: RMB

Item	For the Reporting Period	From the beginning of the year to the end of the Reporting Period
Gains and losses on disposal of non-current assets (including the reversal of previously recognized asset impairment provisions)	-303,991.87	-380,432.23
Government grants recognized in profit or loss for the current period (excluding government grants that are closely related to the business of the Company and are provided in fixed amount or quantity continuously according to the applicable polices and standards of the country).	44,861,228.31	97,182,195.46
Excluding effective hedging activities related to the company's ordinary operating business, this refers to gains and losses arising from changes in the fair value of financial assets and financial liabilities held by non-financial enterprises, as well as gains and losses from the disposal of financial assets and financial liabilities.	15,453,330.81	-1,320,002.12
Other non-operating income and expenses excluding the above items	-8,178,945.07	-13,068,229.51
Less: Effect of income tax	6,413,048.49	12,226,800.99
Effect of minority equity (after tax)	21,757,822.99	32,008,082.76
Total	23,660,750.70	38,178,647.85

For the items not listed in the “Explanatory Announcement No.1 for Public Company Information Disclosures-Extraordinary Gains or Losses” that the company identifies as non-recurring gains and losses, especially those with significant amounts, as well as the extraordinary gain or loss items as illustrated in the “Explanatory Announcement No.1 for Public Company Information Disclosures-Extraordinary Gains or Losses” which has been defined as its recurring gain or loss items, the reasons for such classification should be explained.

□Applicable √N/A

(III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof

□Applicable √N/A

(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and Reasons Thereof

Unit: Yuan Currency: RMB

Balance Sheet	30 September 2024	31 December 2023	Change in proportion (%)	Main Reason
Other receivables	85,854,197.50	46,010,624.61	86.60	Mainly due to the stock options exercised by employees of the subsidiary Livzon Group this period have not yet received the corresponding payment.
Non-current assets due within one year	650,845,317.12	406,376,425.44	60.16	Mainly due to an increase in time deposits maturing within one year.

Other current assets	294,526,056.46	77,402,185.01	280.51	Mainly due to new short-term cash management activities.
Other non-current financial assets	1,399,815,097.39	957,224,255.77	46.24	Mainly due to new cash management activities.
Financial liabilities held for trading	267,731.76	86,817.12	208.39	Mainly due to changes in the fair value of forward foreign exchange contracts.
Contract liabilities	98,823,153.11	159,082,637.65	-37.88	Mainly due to the recognition of revenue from contract advances that met the criteria for revenue recognition during this period.
Taxes payable	271,059,346.85	410,202,854.09	-33.92	Mainly due to a decrease in corporate income tax payable this period.
Non-current liabilities due within one year	1,930,684,639.47	718,564,144.31	168.69	Mainly due to the transfer of long-term loans maturing within one year.
Other current liabilities	12,832,993.44	51,087,001.83	-74.88	Mainly due to a decrease in estimated refund liabilities.
Long-term loans	1,372,606,325.72	3,122,273,278.99	-56.04	Mainly due to the reclassification of long-term loans maturing within one year to current liabilities.
Other comprehensive income	-65,054,363.34	-12,246,131.22	N/A	Mainly due to changes in the fair value of other equity instruments and fluctuations in exchange rates, resulting in variations in foreign currency translation adjustments.
Statement of Income	January to September 2024	January to September 2023	Change in proportion (%)	Main Reason
Financial expenses	-105,969,421.63	-314,423,140.18	N/A	Mainly due to a decrease in interest income from deposits and fluctuations in foreign exchange gains and losses.
Gains from changes in fair value	-5,736,443.62	-46,003,628.22	N/A	Mainly due to fluctuations in the market value of held securities investments.
Losses of credit impairment	-797,210.83	-17,737,505.85	N/A	Mainly due to a decrease in long-aged accounts receivable, leading to a corresponding reduction in expected credit impairment losses.
Impairment loss of assets	-370,399.04	-200,478.63	N/A	Mainly due to an increase in losses from the disposal of fixed assets.
Other comprehensive income, net of tax	-86,688,069.37	-22,658,520.87	N/A	Mainly due to changes in the fair value of other equity instrument investments and fluctuations in exchange

				rates, resulting in variations in foreign currency translation adjustments.
Cash Flow Statement	January to September 2024	January to September 2023	Change in proportion (%)	Main Reason
Net cash flows from investing activities	-1,183,961,052.92	-675,752,976.46	N/A	Mainly due to a higher amount of investment payments made during the current period.

II. SHAREHOLDERS

(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with Restored Voting Rights and Shareholdings of Top 10 Shareholders

Unit: shares

Total number of holders of ordinary shares as of the end of the Reporting Period	76,823	Total number of holders of preferred shares with restored voting rights as of the end of the Reporting Period (if any)	0			
Shareholdings of the top 10 shareholders (excluding shares lent through refinancing business)						
Name of shareholder	Nature of shareholder	Number of shares held	Percentage (%)	Number of shares held with selling restrictions	Pledge, mark or lock-up	
					Share status	Number
Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源投资有限公司)	Domestic non-state-owned legal person	895,653,653	47.79	0	Pledge	55,679,725
Hong Kong Securities Clearing Company Limited	Unknown	97,098,746	5.18	0	Unknown	
Might Seasons Limited	Foreign legal person	35,929,699	1.92	0	Unknown	
Agriculture Bank of China Limited-CSI 500 Exchange Traded Index Securities Invest Fund	Unknown	20,006,912	1.07	0	Unknown	
Perseverance Asset Management L.L.P–Gaoyi Xiaofeng No. 2 Zhixin Fund	Unknown	14,364,600	0.77	0	Unknown	
China Foreign Economy and Trade Trust Co., Ltd.–Foreign Trust–Gaoyi Xiaofeng Hongyuan Collection Fund Trust Plan	Unknown	13,130,100	0.70	0	Unknown	
Rui Life Insurance Co., Ltd. - Own fund	Unknown	12,729,218	0.68	0	Unknown	
Abu Dhabi Investment Authority	Foreign legal person	12,502,378	0.67	0	Unknown	
CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-profit insurance-CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan	Unknown	10,170,000	0.54	0	Unknown	
Bank of Shanghai Co., Ltd. –Yinhua CSI Innovative Drug Industry Trading Open-end Index Securities Investment Fund	Unknown	9,836,796	0.52	0	Unknown	
Shareholdings of the top 10 shareholders without selling restrictions (excluding shares lent through refinancing business)						
Name of shareholder	Number of tradable shares held without selling restrictions	Class and number of shares				
		Class of shares	Number			

Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源投资有限公司)	895,653,653	Ordinary shares denominated in Renminbi	895,653,653
Hong Kong Securities Clearing Company Limited	97,098,746	Ordinary shares denominated in Renminbi	97,098,746
Might Seasons Limited	35,929,699	Ordinary shares denominated in Renminbi	35,929,699
Agriculture Bank of China Limited-CSI 500 Exchange Traded Index Securities Invest Fund	20,006,912	Ordinary shares denominated in Renminbi	20,006,912
Perseverance Asset Management L.L.P-Gaoyi Xiaofeng No. 2 Zhixin Fund	14,364,600	Ordinary shares denominated in Renminbi	14,364,600
China Foreign Economy and Trade Trust Co., Ltd.-Foreign Trust-Gaoyi Xiaofeng Hongyuan Collection Fund Trust Plan	13,130,100	Ordinary shares denominated in Renminbi	13,130,100
Rui Life Insurance Co., Ltd. - Own fund	12,729,218	Ordinary shares denominated in Renminbi	12,729,218
Abu Dhabi Investment Authority	12,502,378	Ordinary shares denominated in Renminbi	12,502,378
CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-profit insurance-CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan	10,170,000	Ordinary shares denominated in Renminbi	10,170,000
Bank of Shanghai Co., Ltd. -Yinhua CSI Innovative Drug Industry Trading Open-end Index Securities Investment Fund	9,836,796	Ordinary shares denominated in Renminbi	9,836,796
Description of connection or acting-in-concert relationship of the above shareholders	There was no connection or acting-in-concert relationship between Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the Company, and other shareholders; whether there is connection or acting-in-concert relationship among other shareholders is unknown.		
Description of the participation of the top 10 shareholders and the top 10 shareholders without selling restrictions in margin financing and securities lending and refinancing business (if any)	N/A		

Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholders without selling restriction in securities lending transactions of refinancing business

√Applicable □N/A

Unit: shares

Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholders without selling restriction in securities lending transactions of refinancing business								
Name of shareholder (Full name)	Number of shares held in ordinary and credit accounts at the beginning of the Period		Number of shares lent through refinancing business and not yet returned at the beginning of the Period		Number of shares held in ordinary and credit accounts at the end of the Period		Number of shares lent through refinancing business and not yet returned at the end of the Period	
	Total number	Proportion (%)	Total number	Proportion (%)	Total number	Proportion (%)	Total number	Proportion (%)
Agriculture Bank of China Limited-CSI 500 Exchange Traded Index Securities Invest Fund	5,055,774	0.27	1,509,200	0.08	20,006,912	1.07	0	0.00
Bank of Shanghai Co., Ltd. - Yinhua CSI Innovative Drug Industry Trading Open-end Index Securities Investment Fund	8,458,496	0.45	10,000	0.001	9,836,796	0.52	0	0.00

Changes in the top 10 shareholders and the top 10 shareholders without selling restriction due to securities lending/returning transactions of refinancing business compared to the previous period

□Applicable √N/A

III. OTHER REMINDERS

Other important information regarding the Company's operations during the Reporting Period to which investors should be reminded to pay attention.

Applicable N/A

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Audit Opinion

Applicable N/A

(II) Financial Statements

Consolidated Balance Sheet

30 September 2024

Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.

Unit: Yuan Currency: RMB Audit status: Unaudited

Item	30 September 2024	31 December 2023
Current assets:		
Monetary funds	14,594,801,258.03	15,691,888,314.83
Financial assets held for trading	77,343,625.25	82,899,154.24
Notes receivable	1,840,201,163.60	1,941,200,568.00
Accounts receivable	2,672,357,170.76	2,692,941,866.24
Receivables financing		
Prepayments	306,162,056.96	280,102,860.94
Other receivables	85,854,197.50	46,010,624.61
In which: Interests receivable		
Dividends receivable		
Inventories	2,605,104,655.82	2,655,808,391.09
Contract assets		
Assets held-for-sale		
Non-current assets due within one year	650,845,317.12	406,376,425.44
Other current assets	294,526,056.46	77,402,185.01
Total current assets	23,127,195,501.50	23,874,630,390.40
Non-current assets:		
Debt investment		
Other debt investment		
Long-term receivables		
Long-term equity investment	1,467,317,916.58	1,411,036,353.95
Other equity instrument investments	1,066,048,054.16	1,155,283,408.36
Other non-current financial assets		
Investment properties	16,327,550.42	16,958,213.00
Fixed assets	5,638,056,264.70	5,664,352,555.97
Construction in progress	662,547,623.17	531,059,118.06
Productive biological assets		
Oil and gas assets		
Right-of-use assets	28,190,760.95	36,233,067.49
Intangible assets	731,856,861.97	683,337,333.73
Development expenditures	461,930,852.53	483,494,487.17
Goodwill	636,339,503.82	636,339,503.82
Long-term deferred expenses	317,024,375.10	328,642,740.95
Deferred income tax assets	619,849,919.58	579,534,830.15
Other non-current assets	1,399,815,097.39	957,224,255.77
Total non-current assets	13,045,304,780.37	12,483,495,868.42
Total assets	36,172,500,281.87	36,358,126,258.82
Current liabilities:		
Short-term loans	2,050,000,000.00	2,076,159,347.22
Financial liabilities held for trading	267,731.76	86,817.12
Notes payable	1,433,953,960.81	1,469,148,287.38
Accounts payable	832,051,361.15	894,286,243.28
Receipts in advance		
Contract liabilities	98,823,153.11	159,082,637.65
Employee benefits payable	382,925,497.74	399,466,473.91
Taxes payable	271,059,346.85	410,202,854.09
Other payables	3,553,679,167.04	3,682,604,038.73
In which: Interests payable		

Dividends payable	10,022,086.38	12,478,280.13
Liabilities held-for-sale		
Non-current liabilities due within one year	1,930,684,639.47	718,564,144.31
Other current liabilities	12,832,993.44	51,087,001.83
Total current liabilities	10,566,277,851.37	9,860,687,845.52
Non-current liabilities:		
Long-term loans	1,372,606,325.72	3,122,273,278.99
Bonds payable		
Lease liabilities	12,031,618.67	15,422,948.41
Long-term payables		
Long-term payroll payable		
Estimated liabilities		
Deferred income	334,243,550.30	370,179,550.82
Deferred income tax liabilities	252,362,201.09	260,032,144.44
Other non-current liabilities	90,000,000.00	90,000,000.00
Total non-current liabilities	2,061,243,695.78	3,857,907,922.66
Total liabilities	12,627,521,547.15	13,718,595,768.18
Owner's equity (or shareholder's equity):		
Paid-in capital	1,874,200,420.00	1,865,523,807.00
Other equity instruments		
In which: Preferred shares		
Perpetual debts		
Capital reserve	1,592,054,957.78	1,601,720,087.71
Less: Treasury shares		
Other comprehensive income	-65,054,363.34	-12,246,131.22
Special reserve		
Surplus reserve	859,046,203.77	859,046,203.77
Undistributed profits	10,227,527,392.35	9,441,857,956.80
Total owner's equity (or shareholder's equity) attributable to the parent	14,487,774,610.56	13,755,901,924.06
Minority shareholder's equity	9,057,204,124.16	8,883,628,566.58
Total owner's equity (or shareholder's equity)	23,544,978,734.72	22,639,530,490.64
Total liabilities and owner's equity (or shareholder's equity)	36,172,500,281.87	36,358,126,258.82

Person-in-charge of the
Company: Zhu Baoguo

Person-in-charge of the
Company's accounting work:
Qiu Qingfeng

Person-in-charge of the
accounting department:
Guo Chenlu

Consolidated Income Statement

From January to September, 2024

Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.

Unit: Yuan Currency: RMB Audit status: Unaudited

Item	First three quarters (January to September) for 2024	First three quarters (January to September) for 2023
I. Total revenues	11,898,828,905.02	12,651,257,386.44
In which: Operating revenues	11,898,828,905.02	12,651,257,386.44
II. Total operating costs	9,121,682,123.61	9,992,088,727.85
In which: Operating costs	4,393,919,087.41	4,836,588,741.76
Operating tax and surcharges	137,567,242.03	150,278,107.37
Selling expenses	2,951,059,287.90	3,428,038,993.64
Administrative expenses	708,729,617.84	680,009,158.86
R&D expenses	1,036,376,310.06	1,211,596,866.40
Financial expenses	-105,969,421.63	-314,423,140.18
In which: Interest expenses	94,972,898.62	106,424,878.84
Interest income	245,985,558.70	373,189,603.11
Add: Other income	124,184,202.58	150,725,832.49
Income from investments (loss is indicated by“-”)	51,650,239.89	58,569,845.80
In which: Income from investments in associates and joint ventures	34,370,020.06	57,873,393.21
Gains from derecognition of financial assets at amortized cost		
Gains from net exposure hedges (loss is indicated by“-”)		
Gains from changes in fair values (loss is indicated by“-”)	-5,736,443.62	-46,003,628.22
Losses of credit impairment (loss is indicated by“-”)	-797,210.83	-17,737,505.85
Assets impairment loss (loss is indicated by“-”)	-113,694,072.70	-108,440,945.45
Gains from disposal of assets (loss is indicated by“-”)	-370,399.04	-200,478.63
III. Operating profit (loss is indicated by“-”)	2,832,383,097.69	2,696,081,778.73
Add: Non-operating income	6,920,279.40	6,302,873.99
Less: Non-operating expenses	19,988,508.91	23,765,998.31
IV. Total profit (loss is indicated by“-”)	2,819,314,868.18	2,678,618,654.41
Less: Income tax expenses	385,618,343.11	433,823,342.57
V. Net profit (loss is indicated by“-”)	2,433,696,525.07	2,244,795,311.84
(I) Classified by business continuity		
1. Net profit from ongoing operation (loss is indicated by“-”)	2,433,696,525.07	2,244,795,311.84
2. Net profit from discontinuing operation (loss is indicated by“-”)		
(II) Classified by ownership		
1. Net profit attributable to shareholders of the parent (loss is indicated by“-”)	1,111,560,063.92	1,083,649,154.75
2. Profit and loss of minority shareholders (loss is indicated by“-”)	1,322,136,461.15	1,161,146,157.09

VI. Other comprehensive income, net of tax	-86,688,069.37	-22,658,520.87
(I) Other comprehensive income attributable to owners of the parent, net of tax	-59,369,859.17	1,005,760.40
1. Other comprehensive income that cannot be reclassified into profit or loss	-58,031,748.84	-31,488,647.75
(1) Changes from remeasurement of defined benefit plans		
(2) Other comprehensive income that cannot be reclassified into profit or loss under the equity method		
(3) Changes in fair value of investments in other equity instruments	-58,031,748.84	-31,488,647.75
(4) Changes in fair value of the enterprise's own credit risks		
2. Other comprehensive income that will be reclassified into profit or loss	-1,338,110.33	32,494,408.15
(1) Other comprehensive income that can be reclassified into profit or loss under the equity method	-174,001.08	164,225.81
(2) Changes in fair value of other debt investments		
(3) Amount of financial assets reclassified into other comprehensive income		
(4) Provision for credit impairment of other debt investments		
(5) Reserve for cash flow hedges		
(6) Exchange translation differences on financial statements denominated in foreign currencies	-1,164,109.25	32,330,182.33
(7) Others		
(II) Other comprehensive income attributable to minority shareholders, net of tax	-27,318,210.20	-23,664,281.27
VII. Total comprehensive income	2,347,008,455.70	2,222,136,790.97
(I) Total comprehensive income attributable to owners of the parent company	1,052,190,204.75	1,084,654,915.15
(II) Total comprehensive income attributable to minority shareholders	1,294,818,250.95	1,137,481,875.82
VIII. Earnings per share		
(I) Basic earnings per share (RMB/share)	0.5945	0.5682
(II) Diluted earnings per share (RMB/share)	0.5944	0.5663

Person-in-charge of the
Company: Zhu Baoguo

Person-in-charge of the
Company's accounting work:
Qiu Qingfeng

Person-in-charge of the
accounting department:
Guo Chenlu

Consolidated Cash Flow Statement

From January to September, 2024

Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.

Unit: Yuan Currency: RMB Audit status: Unaudited

Item	First three quarters (January to September) for 2024	First three quarters (January to September) for 2023
I. Cash flow from operating activities:		
Cash received from sales of goods and rendering of services	12,943,223,324.92	13,510,230,759.20
Tax refunds received	101,353,328.18	141,490,762.85
Other cash received related to operating activities	422,265,935.11	620,955,869.98
Subtotal of cash inflow from operating activities	13,466,842,588.21	14,272,677,392.03
Cash paid for goods and services	3,827,753,296.70	4,573,141,561.87
Cash paid to and on behalf of employees	1,933,905,112.85	1,764,671,591.22
Payments of all types of taxes	1,480,113,236.04	1,416,153,712.56
Other cash paid related to operating activities	3,611,465,441.56	4,058,858,781.68
Subtotal of cash outflow in operating activities	10,853,237,087.15	11,812,825,647.33
Net cash flow from operating activities	2,613,605,501.06	2,459,851,744.70
II. Cash flow from investing activities:		
Cash received from disposal of investment	684,870,511.47	390,344,459.46
Cash received from investment income	21,390,153.27	70,124,524.03
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	474,130.00	8,042,426.01
Net cash received from disposal of subsidiaries and other business units	8,392,000.00	
Other cash received related to investing activities		297,590,000.00
Subtotal of cash inflow from investing activities	715,126,794.74	766,101,409.50
Cash paid for purchase and construction of fixed assets, intangible assets and other long-term assets	737,034,937.83	753,228,828.13
Cash paid for investment	1,160,648,306.49	439,136,113.68
Net cash paid for acquisition of subsidiaries and other business units		22,461,951.59
Other cash paid related to investing activities	1,404,603.34	227,027,492.56
Subtotal of cash outflow in investing activities	1,899,087,847.66	1,441,854,385.96
Net cash flow from investing activities	-1,183,961,052.92	-675,752,976.46
III. Cash flow from financing activities:		
Cash received from capital contribution	261,660,059.73	18,056,784.20
In which: Cash received from investment by minority interests of subsidiaries	165,101,999.95	6,700,000.00
Cash received from borrowings	3,730,993,152.42	3,347,170,168.70
Other cash received related to financing activities	1,062,615.02	20,000,000.00
Subtotal of cash inflow from financing activities	3,993,715,827.17	3,385,226,952.90
Cash repayments of amounts borrowed	4,293,197,628.28	2,592,352,425.04
Cash payments for interest expenses and distribution of dividends or profits	1,447,407,636.60	1,570,166,936.38
In which: Dividends and profit paid minority interests of subsidiaries	1,007,311,935.18	1,120,761,303.69
Other cash payments related to financing activities	400,728,019.90	1,210,358,606.39
Subtotal of cash outflow in financing activities	6,141,333,284.78	5,372,877,967.81

Net cash flow from financing activities	-2,147,617,457.61	-1,987,651,014.91
IV. Effect of exchange rate fluctuations on cash and cash equivalents	-37,426,542.59	71,991,155.94
V. Net increase in cash and cash equivalents	-755,399,552.06	-131,561,090.73
Add: Opening balance of cash and cash equivalents	15,340,869,372.73	14,178,465,686.40
VI. Closing balance of cash and cash equivalents	14,585,469,820.67	14,046,904,595.67

Person-in-charge of the
Company: Zhu Baoguo

Person-in-charge of the
Company's accounting work:
Qiu Qingfeng

Person-in-charge of the
accounting department:
Guo Chenlu

(III) Implementation of new accounting standards or interpretations of standards, for the third time from 2024 involves adjustments to the financial statements at the beginning of the year

Applicable N/A

Hereby the announcement is made.

Joincare Pharmaceutical Group Industry Co., Ltd.
24 October, 2024